Connection
Marc Bonaca to Percutaneous Coronary Intervention
This is a "connection" page, showing publications Marc Bonaca has written about Percutaneous Coronary Intervention.
|
|
Connection Strength |
|
 |
|
 |
|
1.316 |
|
|
|
-
Sidhu MS, Lyubarova R, Bangalore S, Bonaca MP. Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. Am Heart J. 2022 04; 246:44-64.
Score: 0.512
-
Kubica J, Adamski P, Badariene J, Bonaca M, Buszman P, Gabulova R, Gajda R, Geisler T, Gil R, Gorog DA, Gurbel PA, Hajdukiewicz T, Hudzik B, James S, Jeong YH, Kern A, Kochman W, Kubica A, Kuliczkowski W, Magielski P, Niezgoda P, Ostrowska M, Raggi P, Rahimov U, Skonieczny G, Siller-Matula JM, Specchia G, Szarpak L, Szymanski P, Tantry U, Uminska J, Navarese EP. Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators' viewpoint. Cardiol J. 2025; 32(2):189-194.
Score: 0.160
-
Casula M, Casu G, Talanas G, Spano A, Tantry U, Bilotta F, Micheluzzi V, Merella P, Porcheddu T, Gorog DA, Bonaca M, Jeong YH, Farkouh ME, Kubica J, Isgender M, Gurbel PA, Navarese EP. Efficacy and Safety of P2Y12 monotherapy vs standard DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials. Curr Probl Cardiol. 2024 Aug; 49(8):102635.
Score: 0.151
-
Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, ?pinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 09 07; 10(17):e020446.
Score: 0.125
-
Les?n E, Hewitt C, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Maggioni AP, Simeone JC, Ariza-Sol? A, Storey RF, Ten Berg J, Bonaca M. Extended dual antiplatelet therapy with ticagrelor 60?mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. Clin Cardiol. 2021 Oct; 44(10):1333-1343.
Score: 0.125
-
Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute?Coronary Syndrome. J Am Coll Cardiol. 2020 03 17; 75(10):1095-1106.
Score: 0.113
-
Bonaca MP, Wiviott SD. Prasugrel Versus Ticagrelor: Uncertainty Remains. Circulation. 2016 11 22; 134(21):1613-1616.
Score: 0.090
-
Valgimigli M, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, Capodanno D, Cohen DJ, Gibson CM, James S, Kimura T, Lopes RD, Mehta SR, Montalescot G, Sibbing D, Steg PG, Stone GW, Storey RF, Vranckx P, Windecker S, Mehran R. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024 Jul 23; 150(4):317-335.
Score: 0.038
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|